GlobeNewswire

Initial Dan-NICAD II results presented today at ESC

Share

Press release
Malmö, Sweden, August 27, 2021

Initial Dan-NICAD IIresultspresented today at ESC

Study confirms excellent rule-out capacity of CADScor®, almost 50% of intermediate CAD risk patients can be deferred from further diagnostic testing.

A large proportion of patients presenting with chronic chest pain have intermediate risk of CAD (Coronary Artery Disease). The ESC guidelines (2019) point out the challenges in establishing a clear strategy for deferral or referral of these patients.

The Dan-NICAD II trial was initiated in January 2018 to assess non-invasive methods in patients referred to Coronary Computed Tomography Angiography due to symptoms suggestive of obstructive CAD, including the novel CADScor®System from Acarix AB.

The original Dan-NICAD I study demonstrated the high negative predictive value of CADScor® in a cohort of 1,675 patients with suspected stable CAD.

The Dan-NICAD II study aims to further establish diagnostic accuracy in additional 1,732 patients in an expanded age group from 30 years with a special focus on intermediate risk patients.

“With the high negative predictive value of 95%, the Dan-NICAD II results confirm the potential of the CADScor®System for early rule out of CAD.
Interestingly, the CADScor®System has reclassification properties in intermediate CAD risk patients where almost 50% can be deferred from further testing without increasing obstructive CAD risk. Thus, the CADScor®System can potentially supplement clinical assessment to guide decisions on the need for further testing.” says coordinating investigator, MD Laust Dupont Rasmussen from Gødstrup Hospital, Denmark.

“Today, many patients at intermediate risk of CAD are referred to costly and time-consuming diagnostic tests. The Dan-NICAD II results confirm the strength of CADScor® at an early stage of the patients’ journey. The intermediate risk patients represent up to 50% of all patients seeking evaluation for stable chest pain” says Per Persson, CEO Acarix

For further information, please contact:
Per Persson, CEO, E-mail: per.persson@acarix.com, Phone: +46 73 600 59 90

The information was released for public disclosure, through the agency of the contact person above, on August 27, 2021 at 11.30 CET.

About Acarix:
Acarix was established in 2009 and is listed on Nasdaq First North Premier Growth Market (ticker: ACARIX). Acarix’s CADScor®System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-one system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen. Readout is obtained in less than 10 minutes. Safe and suitable for use in both out- and inpatient settings, the CADScor®System thus has the potential to play a major role in patient triage, avoiding the need for many patients to undergo stressful invasive diagnostic procedures. Redeye AB (+46 (0)8 121 576 90, certifiedadviser@redeye.se) is Certified Adviser to Acarix. For more information, please visit www.acarix.com.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Gordon Brothers Names Karl Werner President, International Commercial & Industrial21.9.2021 15:00:00 CEST | Press release

Boston, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Gordon Brothers, the global advisory, restructuring and investment firm, has named Karl Werner President, International Commercial & Industrial. Werner, a former Ritchie Bros. executive, will join the senior leadership team to further develop and execute investment and disposition strategies across the firm’s International Commercial & Industrial practice. He and his team will partner with companies, their investors, lenders and advisors to overcome operational challenges, transform their businesses and dispose of assets. Werner comes to Gordon Brothers with an impressive 30-year track record in global asset management and disposition. He demonstrates innovative leadership in the commercial, industrial and auction industries where his teams have generated more than $1 billion in annual sales. “We are delighted to welcome Karl to Gordon Brothers,” said Frank Morton, CEO of International for Gordon Brothers. “He is a talented and consummate lead

Novozymes is combining cutting-edge science and business expertise to help feed the world sustainably21.9.2021 12:17:09 CEST | Press release

To feed a growing population, Novozymes is inviting all interested parties to help co-create and innovate the future of sustainable protein. By combining science with business expertise Novozymes wants to rethink how protein is made and sourced by enabling a new and progressive industry to provide sustainable nutrition. COPENHAGEN, DENMARK – 21 September, 2021 – As the U.N. Food System Summit sets the stage to bring about tangible, positive changes to the world’s food systems, Novozymes, the world leader in biological solutions, wants to rethink the way we manufacture and source protein. Novozymes announces the launch of the Myco-protein Innovation Call – a global platform to cultivate new business collaborations to scale up the most promising innovations and ideas around how to use fungi as a source of protein. “Realizing the importance of rethinking how we expand the adoption of plant-based protein and how we meet an increasing demand for sustainable nutrition, Novozymes is launching

Biotalys to Participate in Upcoming Investor and Stakeholder Events21.9.2021 12:00:00 CEST | Press release

Ghent, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Press release Biotalysto Participate in Upcoming Investor and Stakeholder Events Ghent, BELGIUM – 21September2021– Biotalys (Euronext - BTLS), an AgTech company focused on addressing food protection challenges to enable a more sustainable and safer food supply, today announces that it will be presenting at the following events during the remainder of 2021: Bryan-Garnier Food Tech Virtual Conference, 23-24 September CEO Patrice Sellès and CFO Wim Ottevaere will be speaking at Bryan Garnier & Co.’s Food Tech Conference on Friday 24 September at 15:00 CEST to an international audience of investors, with a presentation and Q&A session. Knowledge for Growth (FlandersBio), 28 September Biotalys will give a company presentation and participate in a panel debate on Europe’s Farm to Fork strategy at Knowledge for Growth on Tuesday 28 September 2021, at 14:00 CEST. The conference takes place in Ghent and is attended by decision makers from the biotech, p

TGS Share Repurchase21.9.2021 11:11:02 CEST | Press release

Oslo, Norway (21 September 2021) – On period from 16 September 2021 to 20 September 2021, TGS ASA (TGS) purchased 60,000 own shares on the Oslo Stock Exchange at an average price of NOK 83.8969 per share. Following the purchase TGS 1,076,095 own shares, representing 0.917% of the total outstanding shares. The shares were purchased in connection with the share repurchase announced on 11 February 2021. Overview of transactionsDateAggregated daily volume (number of shares)Weighted average share price per day (NOK)Total daily transaction value (NOK)16-Sep-2120,00087.38141,747,62817-Sep-2120,00083.70701,674,14020-Sep-2120,00080.60241,612,048Previously disclosed buy-backs under the program (accumulated)950,995109.5342104,166,514Accumulated under the buy-back program1,010,995108.0127109,200,330The issuer's holding of own shares:Following the completion of the above transactions, TGS owns a total of 1,076,095 own shares, corresponding to 0.917% of TGS' share capital.Appendix:An overview of all

RESULT OF RIKSBANK REVERSED AUCTIONS KOMMUNINVEST BONDS21.9.2021 11:07:00 CEST | Press release

RESULT OF RIKSBANK REVERSED AUCTIONS KOMMUNINVEST BONDS Auction date2021-09-21Loan2505 Coupon1.00 %ISIN-codeSE0011414010Maturity2025-05-12 Tendered volume, SEK mln1,250 +/- 650 Volume offered, SEK mln3,236Volume bought, SEK mln1,250 Number of bids7 Number of accepted bids3 Average yield0.194 %Lowest accepted yield0.190 %Highest yield0.197 %% accepted at lowest yield 83.33 Auction date2021-09-21Loan2611 Coupon1.00 %ISIN-codeSE0012569572Maturity2026-11-12 Tendered volume, SEK mln1,000 +/- 500 Volume offered, SEK mln3,280 Volume bought, SEK mln1,250 Number of bids9Number of accepted bids6 Average yield0.417 %Lowest accepted yield0.415 %Highest yield0.424 %% accepted at lowest yield 77.00 Auction date2021-09-21Loan2805 Coupon0.75 %ISIN-codeSE0015660139Maturity2028-05-12 Tendered volume, SEK mln500 +/- 250 Volume offered, SEK mln1.250Volume bought, SEK mln500 Number of bids3 Number of accepted bids1 Average yield0.608 %Lowest accepted yield0.608 %Highest yield0.608 %% accepted at lowest yie

Mangold Insight presenterar ny analys om Terranets möjligheter21.9.2021 10:14:59 CEST | Pressemelding

I en ny analys upprepar Mangold Insight sin köprekommendation för Terranets aktie efter de senaste framstegen för företaget och med utgångspunkt i den höga aktiviteten i fordonsindustrin. Det expanderande teamet med ett högre kommersiellt fokus lyfts fram i kombination med den patenterade teknologin. Den livräddande VoxelFlow-tekniken kompletterar annan sensorteknologi i dagens fordon. Möjligheten att kunna klassificera och följa objekt upp till hundra gånger snabbare än branschstandarden är dess mest unika attribut, i kombination med den höga bildkvaliteten som teknologin genererar. Du hittar analysen "Snabbare Takt framåt" här: https://bit.ly/3nSsz55 För mer information om Terranet: Pär-Olof Johannesson Tel: +46 70 332 32 62 E-post: parolof.johannesson@terranet.se Om Terranet Terranet (Nasdaq: TERRNT-B.ST). Med visionen att rädda liv utvecklar Terranet sensorteknologi för kollisionsvarning i trafiken. Bolaget levererar mjukvara med tillämningar för avancerat förarstöd och autonoma fo